News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Hatem Soliman, MD

Articles by Hatem Soliman, MD

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

ByKatheryn Moreira,Kathryn Hudson,Wambui Gathirua-Mwangi,Zhanglin Lin Cui,Madeline Richey,Brenda Grimes,Jingru Wang,Astra Liepa,Erich Brechtelsbauer,Raisa Volodarsky,Hatem Soliman, MD

May 24th 2025

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

ByErika P. Hamilton, MD,Lajos Pusztai, MD, DPhil,Hatem Soliman, MD,Sara A. Hurvitz, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Priya Marreddy,Tarek Sahmoud, MD,Nuhad Ibrahim, MD

April 28th 2023

Propelling Immunotherapy Combinations Into the Clinic

ByNishan Tchekmedyian, MD,Jhanelle E. Gray, MD,Benjamin C. Creelan, MD,Alberto A. Chiappori, MD,Amer A. Beg, PhD,Hatem Soliman, MD,Bradford A. Perez, MD,Scott J. Antonia, MD, PhD

December 16th 2015

This review summarizes promising new targets and immunotherapy combination strategies currently under clinical development.

Latest Updated Articles

Propelling Immunotherapy Combinations Into the Clinic
Published: December 16th 2015 | Updated:

Trending on CancerNetwork

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

What Path to Approval Has Dasatinib Taken in CML/ALL?

How Can Lower-Income Countries Maintain Representation in Clinical Trials?

© 2025 MJH Life Sciences^®

All rights reserved.